[1]
Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS) developed with the special contribution of the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J 2014; 35: 2541-619.
[2]
Laidlaw TM, Cahill KN. Current knowledge and management of hypersensitivity to aspirin and NSAIDs. J Allergy Clin Immunol Pract 2017; 5: 537-45.
[3]
Xue Y, Feng ZW, Li XY, et al. The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: A combined clinical study and computational system pharmacology analysis. Acta Pharmacol Sin 2018; 39: 205-12.
[4]
Bianco M, Bernardi A, D’Ascenzo F, et al. Efficacy and safety of available protocols for aspirin hypersensitivity for patients undergoing percutaneous coronary intervention: A survey and systematic review. Circ Cardiovasc Interv 2016; 9: e002896.
[5]
Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005; 95: 509-10.
[6]
Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2012; 126: 875-910.
[7]
Bianco M, Cerrato E, Destefanis P, et al. Management of aspirin intolerance in patients undergoing PCI: The role of mono-antiplatelet therapy - A retrospective multicentre study. Minerva Cardioangiol 2019; 67: 94-101.
[8]
Kenaan M, Seth M, Aronow HD, Wohns D, Share D, Gurm HS. The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin. J Am Coll Cardiol 2013; 62: 2083-9.
[9]
DiNicolantonio JJ, Norgard NB, Meier P, et al. Optimal aspirin dose in acute coronary syndromes: An emerging consensus. Future Cardiol 2014; 10: 291-300.
[10]
Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med 1998; 339: 1665-71.
[11]
Schwartz L, Bourassa MG, Lespérance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318: 1714-9.
[12]
Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393-402.
[13]
D’Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2013; 167: 575-84.
[14]
Gollapudi RR, Teirstein PS, Stevenson DD, et al. Aspirin sensitivity: Implications for patients with coronary artery disease. JAMA 2004; 292: 3017-23.
[15]
Ramanuja S, Breall JA, Kalaria VG. Approach to “aspirin allergy” in cardiovascular patients. Circulation 2004; 110: 1-4.
[16]
Feng CH, White AA, Stevenson DD. Characterization of aspirin allergies in patients with coronary artery disease. Ann Allergy Asthma Immunol 2013; 110: 92-5.
[17]
McMullan KL. Aspirin allergy in patients with myocardial infarction: The allergist’s role. Ann Allergy Asthma Immunol 2014; 112: 90-3.
[18]
Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: Review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy 2011; 66: 818-29.
[19]
Torres MJ, Barrionuevo E, Kowalski M, Blanca M. Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am 2014; 34: 507-24.
[20]
Rossini R, Iorio A, Pozzi R, et al. Aspirin desensitization in patients with coronary artery disease: Results of the multicenter adapted registry (Aspirin desensitization in patients with coronary artery disease). Circ Cardiovasc Interv 2017; 10: e004368.
[21]
Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013; 68: 1219-32.
[22]
Christou A, Kafkas N, Marinakos A, Katsanos S, Papanikitas K, Patsilinakos S. Rapid desensitisation of patients with aspirin allergy who undergo coronary angioplasty. Hellenic J Cardiol 2011; 52: 307-10.
[23]
De Luca G, Verdoia M, Binda G, Schaffer A, Suryapranata H, Marino P. Aspirin desensitization in patients undergoing planned or urgent coronary stent implantation. A single-center experience. Int J Cardiol 2013; 167: 561-3.
[24]
Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid
oral challenge desensitization for patients with aspirin-related urticaria-
angioedema. J Allergy Clin Immunol 2000. 105: 997e1001.
[25]
Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Heart J 2014; 35: 1949-56.
[26]
Kassimis G, Banning AP. Is it time to take bare metal stents off the catheter laboratory shelf? Eur Heart J 2016; 37: 3372-5.
[27]
Urban P, Meredith IT, Abizaid A. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015; 373: 2038-47.
[29]
Vranckx P, Valgimigli M, Windecker S, et al. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: Rationale and design of the global leaders trial. EuroIntervention 2016; 12: 1239-45.
[30]
Baber U, Dangas G, Cohen DJ, et al. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the twilight study. Am Heart J 2016; 182: 125-34.
[31]
Baos S, Underwood W, Culliford L, et al. Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): Study protocol for a randomised controlled trial. Trials 2017; 18: 529.
[32]
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-47.
[33]
Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2011; 124: 544-54.
[34]
Armstrong PC, Leadbeater PD, Chan MV, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011; 9: 552-61.
[35]
Barillà F, Pulcinelli FM, Mangieri E, et al. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. Platelets 2013; 24: 183-8.
[36]
Kim IS, Jeong YH, Park Y, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011; 4: 381-91.
[37]
Cruz-Fernández JM, López-Bescós L, García-Dorado D, et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000; 21: 457-65.
[38]
Fornaro G, Rossi P, Mantica PG, et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Circulation 1993; 87: 162-4.
[39]
Latib A, Ielasi A, Ferri L, et al. Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. Int J Cardiol 2013; 165: 444-7.
[40]
Woessner KM. Aspirin desensitization for cardiovascular disease. Curr Opin Allergy Clin Immunol 2015; 4: 314-22.
[41]
Rossini R, Angiolillo DJ, Musumeci G, et al. Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol 2008; 101: 786-9.
[42]
Tantry US, Gurbel PA. Rapid desensitization of the patients with aspirin hypersensitivity and coronary artery disease. Circ Cardiovasc Interv 2017; 10: e004881.
[43]
Khan DA, Soensky R. Drug allergy. J Allergy Clin Immunol 2010; 125(Suppl. 2): 126-37.
[44]
Cortellini G, Testi S, Severino M, et al. Aspirin challenge/desensitisation before coronary stenting in subjects with history of hypersensitivity. A pragmatic approach. Eur Ann Allergy Clin Immunol 2012; 44: 160-2.
[45]
McMullan KL, Wedner HJ. Safety of aspirin desensitization in patients with reported aspirin allergy and cardiovascular disease. Clin Cardiol 2013; 36: 25-30.
[46]
Lambrakis P, Rushworth GF, Adamson J, et al. Aspirin hypersensitivity and desensitization protocols: Implications for cardiac patients. Ther Adv Drug Saf 2011; 2: 263-70.
[47]
Schiano P, Steg PG, Barbou F, et al. A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI. Eur Heart J Acute Cardiovasc Care 2012; 1: 75-8.
60
3
1